Report cover image

Cell Therapy and Gene Therapy Markets

Publisher Kalorama Information
Published Apr 27, 2020
Length 247 Pages
SKU # KLI16221309

Description

Cell Therapy and Gene Therapy Markets

This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others. Cell Therapy and Gene Therapy Markets presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:
  • Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
  • Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
  • Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
  • Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
  • U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)
The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary. The following conditions/disorders are covered:
  • Dermatology, including:
  • Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
  • Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
  • Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Cardiovascular and Blood Disorders, including:
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
  • Oncology, including:
  • Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
  • Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
  • Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
  • Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Ophthalmic Conditions, including:
  • Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
  • Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)
  • Musculoskeletal Conditions and Disorders, including:
  • Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
  • Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
  • Other Conditions, including:
  • Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
  • Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Cell Therapy and Gene Therapy Markets also includes several discussions on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.

The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:
  • Vitro Biopharma
  • Celularity and Sorrento Therapeutics
  • CanSino Biologics
  • Mesoblast
  • Acturus Therapeutics
  • Entos Pharmaceuticals
  • Zydus Cadila
  • AlloVir and Baylor College of Medicine
  • Athersys
  • Exothera
  • Sirnaomics
  • Mesoblast
    • The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:
  • Advantagene
  • Advaxis
  • AlloSource
  • Alnylam Pharmaceuticals
  • Amgen
  • AnGes USA
  • Anterogen
  • Atara Therapeutics
  • Athersys
  • AveXis
  • BioCardia
  • BioMarin Pharmaceuticals
  • Bluebird bio
  • BrainStorm Cell Therapeutics
  • Caladrius Bioscience
  • Celyad
  • Cook MyoSite
  • Cytori Therapeutics
  • Dendreon
  • Ferring Pharmaceuticals
  • Fibrocell
  • Gamida Cell
  • GenSight Biologics
  • Genzyme
  • Gilead Sciences
  • Gradalis
  • Inovio Pharmaceuticals
  • Kiadis Pharma
  • Medeor Therapeutics
  • Medipost
  • Merck
  • Mesoblast
  • MolMed
  • Neurotech USA
  • Nightstar Therapeutics
  • Northwest Biotherapeutics
  • Novartis
  • NuVasive
  • Orchard Therapeutics
  • Organogenesis
  • Orthofix
  • Osiris Therapeutics (part of Smith & Nephew)
  • Pharmicell
  • Pluristem Therapeutics
  • Quark Pharmaceuticals
  • Renova Therapeutics
  • Sanofi Pasteur
  • SOTIO
  • Spark Therapeutics
  • Tessa Therapeutics
  • Tocagen
  • uniQure
  • VBL Therapeutics
  • ViroMed
Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2019 and expected market for 2020 based on first quarter company reports and is expressed in current dollars. Forecasts are provided through 2025 and an extended forecast for 2030. The size of each market segment refers to manufacturers’ revenues.

*Note: The full report pricing option allows for 1-10 users in a single department*

Table of Contents

247 Pages
    • Overview
    • Scope and Methodology
    • Market Overview and Potential
    • Coronavirus Cell and Gene Therapy Pipeline
    • Introduction
    • Cell and Gene Therapy: Characteristics
    • Staffing
    • Manufacturing Process for CAR-T
    • Advancements and Barriers in Manufacturing Processes
    • Cost
    • Reimbursement
    • Logistics
    • Mergers and Acquisitions
    • Regulatory Developments
    • Development and Pipeline Overview
    • Development Progress
    • Development by Condition/Disorder
    • Phase III Development
    • End User
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Causes of Cancer Growth
    • Global Cancer Burden
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Market Influences
    • Global Market Summary
    • Cell vs. Gene Therapy Markets
    • Regional Market Overview
    • United States
    • Europe/European Union
    • Other Countries
    • Competitor Ranking in Cell and Gene Therapy Markets
    • Leading Influencers
    • Advantagene, Inc.
    • Advaxis, Inc.
    • AlloSource
    • Alnylam Pharmaceuticals
    • Amgen
    • AnGes Inc.
    • Anterogen Co Ltd.
    • Atara Biotherapeutics
    • Athersys, Inc
    • AveXis, Inc.
    • BioCardia
    • Biogen, Inc.
    • BioMarin Pharmaceuticals
    • Brainstorm Cell Therapeutics
    • Caladrius Biosciences
    • Celyad
    • Cook Myosite, Inc
    • Cytori Therapeutics, Inc
    • Dendreon Pharmaceuticals LLC
    • Ferring Pharmaceuticals
    • Fibrocell (Castle Creek Biosciences)
    • Gamida Cell Ltd.
    • GenSight Biologics S.A.
    • Gilead Sciences, Inc.
    • Gradalis, Inc
    • Inovio Pharmaceuticals, Inc.
    • Kiadis Pharma B.V.
    • Medeor Therapeutics
    • Medipost Co, Ltd.
    • Merck & Co., Inc.
    • Mesoblast Ltd.
    • Moderna, Inc
    • Neurotech Pharmaceuticals, Inc.
    • Northwest Biotherapeutics, Inc.
    • Novartis AG
    • NuVasive Biologics
    • Orchard Therapeutics
    • Organogenesis
    • Orthofix Medical Inc.
    • Osiris Therapeutics, Inc.
    • Pharmicell
    • Pluristem Therapeutics, Inc.
    • Quark Pharmaceuticals
    • Regenerative Medical System
    • Renova Therapeutics
    • Sangamo Therapeutics
    • Sanofi
    • SOTIO a.s.
    • Spark Therapeutics
    • Tessa Therapeutics, Ltd.
    • Tocagen, Inc.
    • uniQure N.V.
    • VBL Therapeutics (Vascular Biogenics Ltd.)
    • Vericel Corporation
    • ViroMed Co Ltd (Helixmith)

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us